Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version

This article was originally published in The Pink Sheet Daily

Executive Summary

Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.

You may also be interested in...



Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS

Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.

Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS

Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.

Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss

Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13

Related Content

Topics

UsernamePublicRestriction

Register

PS070481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel